Nichols & Pratt Advisers LLP MA trimmed its stake in CVS Health Corp (NYSE:CVS) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 223,965 shares of the pharmacy operator’s stock after selling 2,050 shares during the period. CVS Health makes up approximately 1.6% of Nichols & Pratt Advisers LLP MA’s portfolio, making the stock its 24th biggest holding. Nichols & Pratt Advisers LLP MA’s holdings in CVS Health were worth $18,200,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of CVS. Hills Bank & Trust Co. boosted its stake in CVS Health by 0.7% in the second quarter. Hills Bank & Trust Co. now owns 46,198 shares of the pharmacy operator’s stock worth $3,717,000 after buying an additional 328 shares in the last quarter. CHICAGO TRUST Co NA boosted its stake in CVS Health by 1.9% in the second quarter. CHICAGO TRUST Co NA now owns 32,221 shares of the pharmacy operator’s stock worth $2,592,000 after buying an additional 587 shares in the last quarter. Private Capital Advisors Inc. boosted its stake in CVS Health by 3.8% in the second quarter. Private Capital Advisors Inc. now owns 8,775 shares of the pharmacy operator’s stock worth $706,000 after buying an additional 325 shares in the last quarter. Creative Planning boosted its stake in CVS Health by 5.0% in the second quarter. Creative Planning now owns 95,488 shares of the pharmacy operator’s stock worth $7,683,000 after buying an additional 4,561 shares in the last quarter. Finally, State of Alaska Department of Revenue boosted its stake in shares of CVS Health by 6.5% during the second quarter. State of Alaska Department of Revenue now owns 53,633 shares of the pharmacy operator’s stock valued at $4,315,000 after purchasing an additional 3,268 shares during the period. Institutional investors own 80.81% of the company’s stock.
In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the transaction, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at $1,166,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.61% of the company’s stock.
CVS Health Corp (NYSE:CVS) traded down $0.32 during midday trading on Wednesday, reaching $69.79. The company had a trading volume of 6,580,000 shares, compared to its average volume of 9,400,000. CVS Health Corp has a 52 week low of $66.45 and a 52 week high of $84.00. The company has a market cap of $70,700.00, a P/E ratio of 11.83, a price-to-earnings-growth ratio of 1.18 and a beta of 0.92. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.52.
CVS Health (NYSE:CVS) last released its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 EPS for the quarter, topping the consensus estimate of $1.88 by $0.04. The company had revenue of $48.39 billion during the quarter, compared to the consensus estimate of $47.54 billion. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. CVS Health’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the company earned $1.71 EPS. equities research analysts anticipate that CVS Health Corp will post 6.44 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th were given a $0.50 dividend. The ex-dividend date of this dividend was Tuesday, January 23rd. This represents a $2.00 annualized dividend and a yield of 2.87%. CVS Health’s payout ratio is 33.90%.
A number of analysts have recently weighed in on CVS shares. Jefferies Group set a $86.00 price objective on CVS Health and gave the company a “hold” rating in a research note on Wednesday, October 18th. Mizuho set a $90.00 price objective on CVS Health and gave the company a “buy” rating in a research note on Tuesday, October 24th. Robert W. Baird reissued a “hold” rating and set a $77.00 price objective on shares of CVS Health in a research note on Friday, October 27th. Loop Capital reaffirmed a “hold” rating on shares of CVS Health in a research note on Friday, October 27th. Finally, Cowen set a $86.00 price target on CVS Health and gave the stock a “buy” rating in a research note on Sunday, October 29th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $87.82.
COPYRIGHT VIOLATION NOTICE: “CVS Health Corp (NYSE:CVS) Position Cut by Nichols & Pratt Advisers LLP MA” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/15/nichols-pratt-advisers-llp-ma-has-18-20-million-holdings-in-cvs-health-corp-cvs-2.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.